Strattera (sometimes misspelled straterra)

Lilly has received FDA approval for a new norepinephrine reuptake inhibitor.  Looking at the pharmacology, this medication is similar to the antidepressant effexor.   But Lilly has done some research to justify the indication for ADD/ADHD. 

This is significant because it's the first nonstimulant to be approved for ADD/ADHD.

And it's the first medication indicated for treating ADHD in adults.